EP1084253A1 - Mimotope des hiv virus - Google Patents

Mimotope des hiv virus

Info

Publication number
EP1084253A1
EP1084253A1 EP99925080A EP99925080A EP1084253A1 EP 1084253 A1 EP1084253 A1 EP 1084253A1 EP 99925080 A EP99925080 A EP 99925080A EP 99925080 A EP99925080 A EP 99925080A EP 1084253 A1 EP1084253 A1 EP 1084253A1
Authority
EP
European Patent Office
Prior art keywords
peptide
seq
phe
thr
ala
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP99925080A
Other languages
English (en)
French (fr)
Inventor
Véronique BARBAN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Pasteur SA
Original Assignee
Aventis Pasteur SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur SA filed Critical Aventis Pasteur SA
Publication of EP1084253A1 publication Critical patent/EP1084253A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Definitions

  • the present invention relates to the treatment and prevention of the HIV virus and in particular to any peptide mimicking new conformational epitopes of antigens of the envelope of the HIV virus and to any polynucleotide integrated in a vector allowing the expression of said peptides and their use for therapeutic, prophylactic, in particular vaccine, and / or diagnostic purposes.
  • HIV is an RNA-enveloped virus and represents the etiological agent of acquired immunodeficiency syndrome or AIDS, the outcome of which is fatal in the long term, characterized by progressive destruction of the immune system and the concomitant development of micro-biological infections causing often due to opportunistic germs.
  • the envelope of the HIV virus derived from the expression product of the Env gene (envelope gene), is first synthesized in the form of a glycoprotein Gp160 which then cleaves into two glycoproteins Gp 120 and Gp 41 These 3 proteins are found on the surface of cells infected with HIV.
  • Gp 160 and Gp 120 have an affinity for the CD4 molecule present on the surface of certain T lymphocytes, a molecule CD4 which acts as a gateway for the HIV virus to enter the cell. So far, very few epitopes accessible to the immune system have been described on the envelope of the HIV virus (Burton DR, 1997 Proc.Natl. Acad. Sci. USA 94: 10018-10023).
  • envelope epitopes which are inducers of neutralizing antibodies, or in other words which are capable of reducing or suppressing viral spread.
  • the present invention aims to overcome these needs by identifying new peptide structures for the therapeutic or prophylactic treatment of HIV infection from the use of a combinatorial library of antibodies from HIV positive patients and belonging to the group.
  • "long term non progressor” the invention relates to any peptide structure capable of reacting with an antibody specific for an antigen of the HIV envelope originating, for example, from a combinatorial library of antibodies obtained from lymphocytes of HIV positive patients. and belonging to the group of "long term non progressors", comprising an amino acid sequence which mimics a conformational epitope of the envelope of said virus without however corresponding to a continuous amino acid sequence of this antigen.
  • the present invention also relates to any recombinant vector comprising a functional expression cassette allowing the expression of a polynucleotide coding for a peptide meeting the criteria defined above.
  • the present invention also relates to a therapeutic or prophylactic composition of the HIV virus, in particular intended for vaccine use, the active principle of which comprises a peptide meeting the criteria defined above and / or a recombinant vector coding for said peptide.
  • a peptide meeting the criteria defined above as a reagent for the diagnosis of the HIV virus making it possible in particular to identify subjects in contact with the virus more resistant to infection, said diagnosis comprising the evaluation, from a blood sample, the humoral and / or cell-mediated response specific for this peptide.
  • Peptide means a sequence of at least 6 amino acids linked together by a peptide bond obtained by chemical synthesis or by genetic recombination techniques, preferably between 6 and 100 amino acids and in particular between 20 and 80 amino acids .
  • Bostolic envelope antigen any molecular entity that binds to an antibody specific for any product derived from the env gene, comprising in particular gp 160 in natural or recombinant form, its derivatives constituted by gp41 and gp 120 may also be in natural or recombinant form and the products derived from the combination of said molecules.
  • “By conformational epitope” means a three-dimensional structure which allows its positioning in the specific binding site of an antibody, like a key in a lock, and which is represented by an amino acid sequence which does not correspond not a continuous amino acid sequence of the protein against which this antibody is raised.
  • this amino acid sequence of the conformational epitope is not homologous to a continuous amino acid sequence of the natural or recombinant protein, the homology being defined by the combination of two criteria:
  • the amino acid identity criterion determined by the ratio between the number of amino acids of a peptide according to the invention which are identical to those of a sequence of the same size carried by the natural or recombinant protein, and the total number of amino acids of said peptide.
  • the identity in amino acids will preferably not exceed 50%, even 60% or 70% or 80% or even 90%.
  • the linking criterion determined by the ratio between the number of amino acids of a peptide according to the invention which are both identical and are in the same linking position as those of a sequence of the same size carried by the natural or recombinant protein, and the total number of amino acids of said peptide.
  • the linking identity will not exceed 70 to 80%.
  • Long term non progressor means HIV positive subjects characterized on the clinical level, in that they do not develop AIDS since they are contaminated with a decline of at least ten years, on the biological level, in what they do not show signs of immunosuppression with in particular a rate of CD4 T lymphocytes higher than 600 / mm 3 and finally not receiving any particular antiviral treatment.
  • “By mimotope” means an epitope which mimics the three-dimensional structure of another epitope by binding to the specific binding site of the same antibody
  • “By CDR3” means the hypervariable amino acid chain region of the heavy and light chain of immunoglobulins and which is located at the site of specific interaction with the epitope.
  • Conjugate means the association of the peptide as defined in the invention with any other molecule, by physical or chemical methods, intended to induce or strengthen the immunogenicity of the starting peptide.
  • Immunogenicity means the ability of a molecular entity, after inoculation into a mammal, to induce production of antibodies specifically directed against this entity.
  • Polynucleotide means either an RNA sequence, or a DNA sequence, or a cDNA sequence resulting from the reverse transcription of a sequence of natural or synthetic origin, with or without modified bases.
  • “Mucosal route” means a mode of administration which brings the pharmaceutical composition directly into contact with the different types of mucous membranes in the body.
  • Parenter route means a mode of administration which puts the pharmaceutical composition directly in contact with the internal tissues or organs of the organism.
  • the invention therefore relates to any peptide which mimics a conformational epitope of an antigen of the HIV envelope and which is recognized by an antibody obtained from a "long term non progressor" patient and specific for this antigen.
  • a peptide according to the invention can be advantageously represented by one of the 11 sequences as follows
  • the selection from this bank of recombinant antibodies specific for antigens of the HIV envelope, in particular expressed by Gp160, Gp120, Gp41 can be in the form of natural or recombinant proteins, glycosylated or deglycosylated, monomeric or multimeric or finally combined or not.
  • the selection of specific recombinant antibodies preferably comprises an additional step consisting in measuring the neutralizing activity of these recombinant antibodies with respect to viral infection mediated in particular by one or more primary isolates of the HIV virus.
  • specific recombinant antibodies which neutralize several primary isolates of the HIV virus.
  • these peptides are mimotopes of conformational HIV epitopes in that there is no correspondence between the amino acid sequence of said peptide with any continuous amino acid sequence found in the proteins of l HIV envelope on the one hand and on the other hand in that this peptide is capable of inhibiting the interaction of the recombinant antibody with the product of the env gene which served for the selection of said recombinant antibody.
  • lymphocytes originating from a "long term non progressor" patient by using, for example the Epstein virus
  • EBV Epstein Barr
  • the lymphocyte transformation process is well known to those skilled in the art and results, after several cycles of selection against the antigen of interest, in obtaining the transformed and immortal lymphocyte clones, each clone producing a single type of monoclonal antibody .
  • These monoclonal antibodies like recombinant antibodies from the combinatorial library, can also be tested for their neutralizing activity against various primary HIV isolates before being used for the selection of mimotope peptides from the HIV envelope.
  • the present invention also relates to peptides comprising a repetition (2 or more) of the peptide according to the invention.
  • the coupling of the two identical peptides can be done if necessary by means of an intermediate spacer arm constituted by the chain of amino acids Gly Pro Gly.
  • the invention also relates to a combination of different peptides according to the invention, as well as to peptides comprising both repeats and combinations.
  • the peptides can be joined by covalent bonds or non-covalent bonds.
  • Posnett et al J. Biol. Chem. (1988) 263: 1719
  • Posnett et al J. Biol. Chem. (1988) 263: 1719
  • the peptides according to the invention can thus be conjugated to known immunogenic proteins such as serum albumin, thyroglobulin, ovalbulmine, gelatin, haemocyanin (eg Keyhole Limpet Haemocyanin KLH), seroglobulins, tetanus toxoid, diphtheria toxoid, proteins from external membranes of bacteria, etc, but it is also possible to prefer to conjugate the peptides with “T helper” epitopes among which the “T helper” epitopes of HIV are chosen, for example the T1 and p24E epitopes as described in WO 94/29339 (Connaught).
  • the conjugation reactions with said "T helper" epitopes of HIV allow us to obtain compounds whose sequential sequence is p24E-GPG-X-GPG-T1 where:
  • -p24E symbolizes the amino acid sequence of the p24E epitope, said sequence being placed on the N-terminal side of the peptide according to the invention;
  • -GPG symbolizes the glycine-proline-glycine sequence;
  • -X symbolizes the peptide of interest according to the invention which may be, if necessary, the product of the combination of several identical or different amino acid sequences in accordance with the invention;
  • -T1 symbolizes the amino acid sequence of the T1 epitope, said sequence being placed on the C-side of the peptide according to the invention
  • conjugates can themselves be grafted onto a branched lysine framework so as to obtain polymers of said conjugates in a branched form as described in WO 94/29339 (Connaught), the technical content of said patent being incorporated by reference into the subject matter of the invention.
  • Heterobifunctional agents such as SPDP, carbodiimide, glutaraldehyde, biotin / avidin system, etc. can be used, for example.
  • the peptides can also be coupled to lipopolysaccharides, polysaccharides, glycopeptides, muramyl peptide analogs, fatty acids, etc.
  • a peptide is coupled with a fatty acid of the palmitoyl-lysine type as described in EP 491628 (Biovector) or (Pam) 3
  • the peptides can also be formulated with alum, monophosphoryl Lipid A, pluronics, SAF1, Ribi, treha! Ose-6,6-dimycolate or other immunostimulatory compounds known to those skilled in the art to increase immunogenicity of the peptide to which these compounds are linked.
  • the present invention also relates to the DNA fragments coding for the peptides according to the invention and which can be used to produce the peptides by expression of the DNA sequence in an appropriate expression system.
  • the expression system is an in vitro expression system for the production of the peptides with a view to their subsequent use, eg as a diagnostic reagent, as an antigenic component or as a vaccine component.
  • Such systems or vectors for in vitro expression are perfectly known to those skilled in the art and mention may be made, for example, of bacteria such as E. coli, eukaryotic cells such as yeasts, in particular S. cerevisiae. , baculovirus, in particular spread on insect cells, etc.
  • the invention therefore also relates to an expression cassette comprising such a DNA fragment and regulatory sequences allowing the expression of this DNA fragment in an appropriate in vitro expression system.
  • the expression system is an in vivo expression system for generating an immune reaction, preferably protective, in the patient treated.
  • the expression system which may be replicative or non-replicative, will express the peptide in vivo. Those skilled in the art have at their disposal such systems.
  • plasmids in particular naked plasmids, eg according to WO-A-90 11092, WO-A-93 19813, WO-A-94 21797 and WO-A-95 20660, poxviruses, such as vaccinia virus and avian pox (fowlpox, pigeonpox, canarypox, etc.), adenoviruses, etc.
  • poxviruses such as vaccinia virus and avian pox (fowlpox, pigeonpox, canarypox, etc.), adenoviruses, etc.
  • the invention therefore also relates to expression cassettes comprising such a DNA fragment and the means for regulating expression in the chosen expression system. It also relates to the expression system or expression vector, comprising such an expression cassette, in particular plasmid, poxvirus, adenovirus, as seen above.
  • the subject of the invention is the use of phages expressing the peptide of interest or a combination of phages expressing the peptides of interest as a diagnostic reagent, as an antigenic component or vaccine.
  • the invention also relates to the use of at least one peptide in accordance with the invention in combination or not with at least one recombinant vector in accordance with the invention for the preparation of a pharmaceutical composition intended for preventing or curing a condition related to the HIV virus.
  • a composition according to the invention can comprise preparations which can be in the form of creams, lyophilized powders or not, solutions, suspensions, for administrations by mucous route such as oral, nasal, rectal, genital, cutaneous, for example.
  • parenteral administration such as intra dermal, subcutaneous, intramuscular, intravenous, intra arterial, intra lymphatic or intra peritoneal, for example, sterile injectable preparations may be in the form of solutions, suspensions or emulsions .
  • the preparations may contain excipients and / or stabilizing agents suitable for the mode of administration.
  • Preparations for vaccine use may also contain adjuvants or be incorporated into delivery systems compatible with use in human medicine.
  • adjuvants such as Alum (aluminum phosphate phosphate or aluminum hydroxide or the mixture of the two) incorporated in a conventional manner in vaccines, the incomplete Freund's adjuvant, monophosphorylated lipid A ( MPL), QS21, Polyphosphazene, muramyl dipeptide (MDP) or its derivatives, the use of antigen delivery systems such as emulsions (MF59, SAF1, RIBI, SB 62, SB 26), ISCOMS, liposomes, microspheres composed of PLGA polymers of well calibrated diameter, or possibly pseudo virions.
  • Alum aluminum phosphate phosphate or aluminum hydroxide or the mixture of the two
  • MPL monophosphorylated lipid A
  • QS21 QS21
  • Polyphosphazene muramyl dipeptide
  • MDP muramyl dipeptide
  • compositions will be determined taking into account the nature of the composition, the level of expression of the peptide of interest by the recombinant vector if it is included in the preparation, the age , sex and weight of the individual receiving the preparation.
  • the relative importance of the carrier molecule in the conjugate will also be taken into account if it is included. in the composition.
  • the doses of peptides administered may reach 1 to 5 mg but more generally will be between 5 ⁇ g and 1 mg per injection, preferably 50 to 500 ⁇ g.
  • the recombinant vector coding for the peptide of interest may be administered or used to transfect or infect the cells of interest at a minimum dose of 10 3 ′ 5 infecting units (pfu or plaque forming unit).
  • the recombinant vector will be used in a dose scale ranging from 10 4 to 10 10 pfu depending on the expression efficiency of the peptide by this vector and in particular in a dose scale ranging from 10 6 to 10 9 pfu, for example.
  • the pharmaceutical composition comprises several recombinant vectors coding for peptides of different interest
  • these same dose scales can be applied to these combinations.
  • Those skilled in the art will be able to refer to the protocols and clinical trials using preparations based on recombinant vectors, in particular recombinant pox viruses, recombinant adenoviruses, already produced in humans to agree on the appropriate number of pfu that must contain pharmaceutical composition.
  • the pharmaceutical composition comprises a plasmid containing the expression system of the peptide of interest
  • the level of immune response that this composition is capable of inducing which must be at least equal to that of. intact or modified peptide and / or the level of expression of the peptide induced by the plasmid in the cells of the organism which must approach as much as possible that obtained by the recombinant vectors already mentioned.
  • the quantities of plasmids contained in the pharmaceutical compositions may be in scales ranging from 1 ⁇ g to 100 mg, preferably between 0.1 mg to 10 mg.
  • the pharmaceutical composition may be administered at once or several times to achieve the desired level of response including in particular the level and quality of the specific antibody response and / or cell-specific mediation desired, and characterized in that it guarantees the protection of the individual against accidental contamination.
  • the chosen administration voice may be necessary, in addition to the composition of the preparation, the chosen administration voice, to respect the time limits set between each injection, which can preferably be 1 month, 2 months or 6 months and / or to make use, in a combined or alternating manner, during the duration of the medical protocol, in particular the vaccine protocol, of different pharmaceutical compositions relating to the peptide, to the recombinant vector, to the plasmid of interest or even to the phages expressing the peptide (s) of interest that the the skilled person is capable of mastering. To maintain the level of protection, it may also be necessary to give booster injections at regular intervals.
  • the pharmaceutical composition for the treatment of HIV-related infection, may be administered at once or several times and in a manner which may be very close together, in particular within periods of less than a week, in order to reach the level desired response, in particular that which makes it possible to ascertain the absence of the HIV virus in the blood by the PCR test.
  • the pharmaceutical composition comprising the peptide, the vector, the plasmid of interest.
  • phages expressing the peptide or peptides of interest may be combined or used alternately with conventional treatments for this condition, including in particular mono , bi or tri antiviral therapy.
  • a pharmaceutical composition comprising one or more peptides of interest, the corresponding recombinant vector (s) as well as the plasmid (s) of interest or even bacteriophages expressing the peptide (s) of interest to stimulate the cells of the patient's immune system in vitro or ex vivo and to then re-inject them into the body of the individual.
  • This methodology was notably developed in the immunotherapeutic treatment of cancer.
  • the subject of the invention is finally the use of the peptides of interest as a reagent for the diagnosis of HIV infection, making it possible in particular to identify subjects more resistant to infection also called “Long term non progressor” or conversely, to identify infected subjects more likely to develop AIDS quickly.
  • new conformational epitopes of the HIV envelope have been defined.
  • peptides can therefore be used, for diagnostic purposes, to preferentially search for neutralizing antibodies to primary isolates of HIV, which very often recognize conformational epitopes and thus make it possible to distinguish individuals "Long term non progressor” (possessing antibodies neutralizers) of those who are likely to progress quickly to AIDS if no treatment, in particular anti-viral, is put in place quickly (not having neutralizing antibodies).
  • the present invention therefore also relates to a method of diagnosing HIV infection and / or of the susceptibility of infected subjects to develop AIDS quickly, the said method being preferably based on the analysis of the humoral response.
  • immunoenzymatic, radioimmunological or western blotting methods well known to those skilled in the art may be used, such as, for example, the ELISA, RIA, RIPA or IRMA methods.
  • Figures 1 to 5 show, depending on their dilution, the phage binding curves expressing respectively the peptide sequences SEQ ID NO: 1;
  • SEQ ID NO: 7 SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, SEQ ID NAME 1 to a recombinant antibody specific for Ggp 160 and derived from the combinatorial library of antibodies made from lymphocytes d 'a subject "long term non progressor" (B) and an IgG antibody not specific for HIV envelope antigen (•), these two antibodies being previously fixed on ELISA plates.
  • the intensity of the fixation is proportional to the value of the optical density (OD) obtained by ELISA.
  • sequences coding for the heavy and light chain parts of the selected Fab molecules can be isolated and synthesized, and cloned in any vector or replicon allowing their expression.
  • Any suitable expression system can be used, for example bacteria, yeasts, insect, amphibian and mammalian cells.
  • Expression systems in the bacteria include those described in Chang et al. (1978) Nature 275: 615, Goeddel et al. (1979) Nature 281: 544, Goeddel et al. (1980) Nucleic Acids Res. 8: 4057, EP-A-36,776, US-A-4,551, 433, deBoer et al. (1983) Proc. Natl. Acad. Sci. USA 80: 21-25, and Siebenlist et al. (1980) Cell 20: 269.
  • the expression systems in yeasts include those described in Hinnen et al. (1978) Proc. Natl. Acad. Sci. USA 75: 1929, Ito et al. (1983) J. Bacteriol. 153: 163, Kurtz et al.
  • heterologous genes in insects can be carried out as described in US-A-4,745,051, EP-A-127,839 and EP-A-155,476, Vlak et al.
  • Biochem. 102 255, US-A-4,767,704, 4,657,866; 4,927,762; 4,560,655; US patent
  • Peripheral blood lymphocytes from a subject infected with the HIV virus and belonging to the group of "long-term non progressors" are used to produce the combinatorial library of antibodies.
  • the lymphocyte cDNA is obtained from RNA using a methodology developed by Sodoyer R. et al. (1997) Human Antibodies 8: 37.
  • the library of heavy and light chains is constructed using the phagemids pVH (pM 831) and pVL (pM452). The two libraries are then associated in a "Random" fashion by sub-cloning of the VL genes in the heavy chain library.
  • the phagemid library obtained is then infected with the phage helper M13 VCS, thus allowing the expression of Fabs on the surface of the phages.
  • the nucleotide sequence of the recombinant Fabs expressed by the positive isolates and in particular the CDR3 sequences carried by the fragments of heavy and light chains is determined.
  • One of the recombinant antibodies specific for Gp 160 originating from this combinatorial library is then used to select the peptide sequences SEQ NOM to SEQ NOM 1 from a commercially available phage library expressing peptides randomly (pHD7, NEB). operating as follows: 1, 4 10 11 phages are incubated with 30 or 300 ng of the recombinant antibody according to example 1 in 200 ⁇ l of PBS-0.1% tween 20 for 20 min at 20 ° C. The mixture is transferred to a tube containing 50 ⁇ l of protein G coupled to sepharose beads previously balanced for 1 hour in 1 ml of PBS-0.1% tween 20 containing 5% skimmed milk. After a further 20 min incubation, the beads are centrifuged and washed 3 times with 1 ml of PBS-0.1% tween 20.
  • Au a commercially available phage library expressing peptides randomly
  • the beads are times with PBS-0.1% tween 20 containing 5% skimmed milk, incubated 10 min, centrifuged and rinsed again three times with PBS
  • the culture volume was made up to 100 ml with LB medium, and the incubation was continued for 4 h at 37 ° C.
  • the phages are precipitated by adding 25 ml of PEG 20% -NaCI 2.5M in the culture supernatant overnight at 4 ° C. After centrifugation (10,000 rpm, 20 min, 4 ° C), the phage residue is taken up in 1 ml of PBS-0.1% tween 20-1% skimmed milk, and titrated. Screening is complete when the whole process has been repeated 3 to 4 times.
  • phages expressing peptide sequences 1 to 11 they were also tested by ELISA as follows: 0.2 mg of recombinant antibody specific for Gp 160 or of an antibody which does not have specificity for an antigen of the envelope of HIV called "control Ig", diluted in 50 ⁇ l of PBS, is deposited in each well of an ELISA plate followed by an incubation overnight at 4 ° C.
  • the various dilutions made are distributed in the wells sensitized either by the specific recombinant antibody according to Example 1, or by the control Ig.
  • the phages are removed by aspiration of the dilutions then the wells washed 10 times with 0.2 ml of PBST.
  • the intensity of coloration of the OPD solution is then measured with a spectrophotometer, then the OD curves (optical density) are established as a function of the dilution of phages.
  • the curves in FIGS. 1 to 5 show, by way of example, that the phages expressing the peptide sequences, SEQ ID NO: 7 to SEQ ID NO: 11 bind well to the specific recombinant antibody (OD> 0.6 observed for at least one dilution of phages) while there is no significant fixation on the control Ig (OD ⁇ 0.3 whatever the dilution of phages tested in the dilution range going from 5 10 11 phages / well at 4.8 10 8 phages / well).
  • the positive phages ie those which bind specifically to the specific recombinant antibody, are amplified in E. Coli.
  • Mini phage DNA preparations are carried out according to the procedures described in the works of Maniatis, the DNA is sequenced using an automatic sequencer from which the sequence of the peptide expressed by the phage is deduced.
  • the ⁇ amino function of the amino acids is protected by the introduction of a t-butyloxycarbonyl (t-boc) group, thus allowing coupling, by the carboxylic function of the amino acid, to an active chloromethylee resin.
  • the amino function is "deprotected” by the action of trifluoroacetic acid followed by a neutralization step with triethylamine.
  • the amino function thus released then undergoes a coupling reaction with another amino acid in the form of a t-boc derivative via carbodiimides.
  • This process is implemented by the ABI automaton (Applied Biosystem Inc) 430A which thus performs the automatic synthesis of peptides.
  • the peptide is detached from the resin by the action of hydrofluoric acid.
  • the extract is then purified by reverse phase HPLC using a Vydac C4 type semi-preparative column and an acetonitrile gradient ranging from 15 to 55% in a 0.1% trifuoroacetic acid solution.
  • Liquid chromatography is programmed for a period of 40 min with a flow rate of 2 ml / min. The purity of the peptides is controlled by analytical chromatography and exceeds 95%.
  • the peptides of SEQ ID NOs: 1 to 6, displayed on phage are injected into guinea pigs and rabbits: two injections of 100 microliters intravenously, 3 weeks apart followed by a final bleeding 15 days after the 2 ee injection.
  • the sera are tested in ELISA against gp160 and a reaction against the glycoprotein is observed. These peptides are therefore capable of inducing a response against gp160. 2) Induction of antibodies in mice
  • the various phage isolates expressing the peptides defined by SEQ ID NO: 7 to SEQ ID NOM 1 are purified on a cesium chloride gradient. 5 groups of BaLB / c mice are then identified. Each group is immunized intraperitoneally, 3 times at 3 week intervals with a single type of purified isolate expressing either SEQ ID NO: 7, or SEQ ID NO: 8 or SEQ ID NO: 9 or SEQ ID NOM0 or SEQ ID NOM 1 at the rate of 10 12 phages purified by injection.
  • mice To compare the antibody responses, we introduced 2 additional groups of mice, the first group receiving 3 injections of 10 12 phages expressing peptides not mimicking conformational epitopes of the HIV envelope (irrelevant phages), the second receiving 3 injections of 5 ⁇ g of Gp160 protein.
  • mice in this group as well as some of the mouse group immunized with the unrelated phages received 4th injection of 5 mcg Gp 160, 3 weeks after the 3 rd injection.
  • the analysis of the specific antibody response is carried out on the serum of the mice of each group taken 15 days after each injection. Analysis of the specific antibody response includes the detection of anti gp 160 antibodies by ELISA using plates sensitized with the Gp 160 protein using a procedure similar to that described in example 1 and the search for antibodies. neutralizers. For the search for neutralizing antibodies, the dilution of serum is determined which prevents the formation of syncytia in 50% of the microwells infected with
  • 10 CCID50 of a strain of HIV virus After decomplementation of the sera and production of a dilution range of reason 2 in RPMI medium, 500 ⁇ l of the suspension of HIV virus titrating 10 2.5 CCID 50 / ml is mixed with 500 ⁇ l of the various dilutions of sera. After an incubation of 2 hours at 37 ° C, the mixture is deposited in a volume of 100 ⁇ l on CEMss cells previously fixed in microwells (6 microwells / dilution of serum). After 1 hour of contact at 37 ° C. with the CEMss cells, the mixture is aspirated and replaced with culture medium.
  • Water-in-oil emulsions are then prepared using squalene as a constituent of the organic phase, tween 80 or a mixture of tween 80 and SPAN as a surfactant, the aqueous phase containing the peptide solution.
  • a vaccine formulation based on liposomes comprising a peptide having one of the sequences SEQ ID NOM to SEQ ID NO: 11 described in the example
  • a vaccine formulation based on ISCOMs is prepared containing a peptide having one of the sequences SEQ ID NOM to SEQ ID NOM 1 described in Example 1 and produced by chemical synthesis according to Example 2 with reference to B Morein et al, 1984, Nature 308: 457 or B Morein et al Immunoiogy toDay, 1987, 8 (11): 333.
  • a formulation based on micro particles comprising a peptide having one of the sequences SEQ ID NOM to SEQ ID NOM 1 described in the example
  • micro particles or nanoparticles many synthetic or natural polymers are used such as the polymer of methyl metacrylate (Troster SD et al, 1992, J. Microencaps. 9:19) but often poly (d, 1 -lactide- co-glycolide) also called PLGA is the referent because of its biodegradability, its safety and its applications already old in the medical field.
  • the PLGA micro particles loaded with peptides are prepared in particular by double water-in-oil-in-water emulsion.
  • the peptide is dissolved in the aqueous phase and then emulsified in a solution of PLGA in the organic phase such as dichloromethane.
  • a solution of PLGA in the organic phase such as dichloromethane.
  • the water in oil emulsion is obtained by high speed stirring of the peptide solution in the organic solution of PLGA.
  • a second aqueous phase containing an appropriate concentration of surfactant such as polyvinyl alcohol is added to the first emulsion to thereby produce the double emulsion.
  • surfactants are also used such as bile salts or poly (oxyethylene glycerol monoleate) to stabilize the double emulsion (Rafati H et al., 1997, Vaccine 15: 1888).
  • This formulation is used for the preparation of a vaccine composition intended for the prevention or treatment of HIV virus infection.
  • Example 8 Vaccine composition
  • Peptides with fewer than 20 amino acids can be weakly immunogenic.
  • a vaccine formulation is prepared based on polymers of the same peptide or different peptides, in the form of octamers comprising a branched poly-lysine structure with 8 lateral arms on which the same peptide or different peptides are fixed according to Example 1 by implementing the method developed by Posnett DN et al. (1988) J. Biol. Chem. 263: 1719.
  • This formulation is used for the preparation of a vaccine composition for the prevention or treatment of HIV virus infection.
  • Example 9 Vaccine composition
  • a vaccine composition comprising a peptide having one of the sequences SEQ ID NAME, SEQ ID NO: 3 or SEQ ID NO: 4 described in Example 1 and produced by chemical synthesis according to Example 2, according to Example 2 framed by the 2 T helper P24E and T epitopes of the HIV virus, these 2 epitopes playing the role of carrier molecule and thus strengthening the immunogenicity of the peptide.
  • the coupling reaction of the peptide with these 2 T helper epitopes is carried out in 2 stages according to conventional methods well known to those skilled in the art.
  • the N-terminal part of the peptide is coupled with the C-terminal part of the peptide sequence representing the p24E epitope by intercalating a space consisting of the glycine-praline-glycine sequence.
  • the terminal C part of the intermediate product is coupled with the N terminal part of the peptide sequence representing the T1 epitope by intercalating the same glycine-proline-glycine sequence to obtain the final product.
  • This formulation is used for the preparation of a vaccine composition intended for the prevention or treatment of HIV virus infection.
  • Example 10 Vaccine composition comprising a lipopeptide
  • a vaccine formulation comprising a peptide having one of the sequences SEQ ID NOM to SEQ ID NOM 1 described in Example 1 and produced by chemical synthesis according to Example 2 coupled to one or more chains derived from fatty acids, including N ⁇ palmitoyl-lysine, N, N-dipalmitoyl-lysine, pimelautide, trimexautide or to a steroid group, including N ⁇ [(cholest-5-enyl-3-oxy) -acetyl)] - iysine or (cholest-5-enyl-3-oxy) acetic acid according to the process described in patent EP0491628 (INSERM) so as to obtain a lipopeptide.
  • This formulation is used for the preparation of a vaccine composition intended for the prevention or treatment of HIV virus infection.
  • a vaccine composition comprising a recombinant poxvirus encoding a peptide having one of the sequences SEQ ID NOM to SEQ ID NOM 1 described in Example 1 mimicking a conformational epitope of the envelope of HIV.
  • Recombinant poxviruses are obtained by homologous recombination from embryonic chicken cells infected with poxviruses and co-transfected with plasmids containing an expression cassette, flanked at the ends of DNA sequences homologous to those of nonessential regions of l Poxvirus DNA, and containing, under the dependence of poxvirus promoters (H6, 13L), the poly nucleotide which codes for the peptide according to Example 2 using the methods described in US Patents 4,769,330, 4,772,848, 4,603,112, 5,100,587 ,
  • a vaccine composition comprising a recombinant poxvirus encoding several peptides having one of the sequences SEQ ID NOM to SEQ ID NOM 1 described in Example 1 mimicking several conformational epitopes of the envelope of HIV.
  • the use and preparation of recombinant vectors coding for several epitopes is well known to those skilled in the art (Toes RE et al. (1997) Proc. Natl. Acad. Sci. USA 94: 14660, Thomson SA et al. (1996) J. Immunol. 157: 822) and is also applicable to the preparation of recombinant poxviruses encoding multiple mimotopes.
  • a vaccine composition comprising a recombinant canaripox (recombinant ALVAC) encoding multiple mimotopes of the HIV envelope.
  • recombinant poxviruses are used for the preparation of a vaccine composition intended for the prevention or treatment of HIV virus infection.
  • a vaccine composition comprising several peptides having one of the sequences SEQ ID NOM to SEQ ID NOM 1 described in example 1 using the different preparation methods described in examples 2 to 12 mimicking several conformational epitopes of the envelope of HIV. These different compositions are used for the preparation of a vaccine composition intended for the prevention or treatment of HIV virus infection.
  • HIV specific antibody detection is carried out by ELISA using one or more peptides having one of the sequences SEQ ID NOM to SEQ ID NOM 1 described in Example 1 and produced by chemical synthesis according to Example 2 for the diagnosis of HIV infection from a biological sample
  • a sample of physiological fluid blood, plasma, serum
  • a sample which is then reacted in the presence of a peptide according to the invention is taken, a sample which is then reacted in the presence of a peptide according to the invention.
  • the peptide itself is used as a diagnostic reagent.
  • an indirect diagnostic test of the ELISA type, in which the peptide fixed on a support (well) is placed in the presence of the sample to be tested, while the revelation of the antigen-antibody binding is ensured by a labeled anti-Ig, either by a competition or displacement test, in which a peptide according to the invention is used, and a labeled antibody specific for the peptide.
  • the peptide is there also fixed to a solid support such as well, strips.
  • the competition test the peptide is placed simultaneously in the presence of the sample
  • sample antibody and a labeled antibody specific for the peptide.
  • Antibodies labeled with peroxidase are generally used.
  • monoclonal and polyclonal antibodies or recombinant antibodies specific for the peptide according to the invention are generally used, which are sometimes Fab or F (ab) 2 fragments and in particular those described in the invention.
  • HIV specific antibody detection is implemented by immunochromatography using one or more peptides according to the invention for the diagnosis of HIV infection from a biological sample
  • the peptide according to the invention is fixed on a strip-type support and reference is made to the article by Robert FN Zurk et al., Clin. Chem. 7/31, 1144-1150 (1985) and in patents or patent applications WO-A-88/08 534, WO-A-
  • EP-A-291 176 91/12528, EP-A-291 176, EP-A-299428, EP-A-291 194, EP-A-284 232, US-A-5 120 643, US-A-5 030 558, US-A -5 266 497, US-A-4 740 468, US-A-5 266 497, US-A-4 855 240, US-A-5 451 504, US-A-5 141 850, US-A-5 232 835 and US-A-5 238 652 for implementing the method.
  • the patient's blood is collected on a heparin tube.
  • the lymphocytes are then separated by centrifugation on hypaque Ficoll and then distributed in 96-well sterile microplates at the rate of 2 ⁇ 10 5 cells per round-bottom well under a final volume of 200 ⁇ l of complete culture medium (RPMI 1640 supplemented with 25 mM HEPES, 2 mM L -glutamine, 50U / ml of penicillin, 50 ⁇ g / ml of streptomycin and 5% serum AB decomplemented) and placed in the presence of variable concentrations of one or more peptides having one of the sequences SEQ ID NOM to SEQ ID NOM 1 described in Example 1 and produced by chemical synthesis according to Example 2 (concentrations ranging from 1ng / ml to 50 ⁇ g / ml).
  • Each concentration of peptide is tested in triplicate to overcome biological variations as well as possible. Multiple combinations of peptides can also be tested in the indicated concentration range, for example a combination resulting from the association of an envelope mimotope with a nucleocapsid mimotope in the indicated concentration range.
  • 0.5 ⁇ ci of tritiated thymidine is added to each well.
  • the cellular DNA is collected from each culture well on filters after precipitation with ethanol and the incorporation rate of tritiated thymidine is measured using a liquid scintillation counter. which reflects the intensity of the lymphoproliferative response.
  • the results are expressed in the form of stimulation index (average of the cpm of the lymphocyte culture wells containing a given concentration of peptide / average of the cpm of the lymphocyte culture wells without peptide).
  • the lymphoproliferative response is considered positive when the stimulation index is greater than 3.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
EP99925080A 1998-06-12 1999-06-14 Mimotope des hiv virus Withdrawn EP1084253A1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR9807598 1998-06-12
FR9807598 1998-06-12
PCT/FR1999/001409 WO1999066046A1 (fr) 1998-06-12 1999-06-14 Mimotopes du virus hiv

Publications (1)

Publication Number Publication Date
EP1084253A1 true EP1084253A1 (de) 2001-03-21

Family

ID=9527466

Family Applications (1)

Application Number Title Priority Date Filing Date
EP99925080A Withdrawn EP1084253A1 (de) 1998-06-12 1999-06-14 Mimotope des hiv virus

Country Status (5)

Country Link
EP (1) EP1084253A1 (de)
AU (1) AU748700B2 (de)
CA (1) CA2331197A1 (de)
NZ (1) NZ508812A (de)
WO (1) WO1999066046A1 (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2603100A (en) * 1999-01-11 2000-08-01 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Novel hiv related peptides
US6911527B1 (en) 1999-01-11 2005-06-28 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services HIV related peptides
FR2818648B1 (fr) * 2000-12-22 2003-10-10 Aventis Pasteur Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih
AU2002219290A1 (en) * 2000-12-22 2002-07-08 Aventis Pasteur Proteinic antigens inducing antibodies neutralising hiv virus
JP5861242B2 (ja) * 2009-04-17 2016-02-16 ナショナル リサーチ カウンシル オブ カナダ クラステリンのペプチドリガンド及びその使用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU693098B2 (en) * 1993-06-09 1998-06-25 Connaught Laboratories Limited Tandem synthetic HIV-1 peptides
WO1995012677A2 (en) * 1993-11-04 1995-05-11 Innogenetics N.V. Immunodominant human t-cell epitopes of hepatitis c virus
DE4405810A1 (de) * 1994-02-23 1995-08-24 Behringwerke Ag Von einem Retrovirus aus der HIV-Gruppe abgeleitete Peptide und deren Verwendung
US5877155A (en) * 1995-03-17 1999-03-02 The Research Foundation Of State University Of New York Mimotopes and anti-mimotopes of human platelet glycoprotein Ib/IX
DE19613253A1 (de) * 1996-04-02 1997-10-09 Immuno Gmbh Technik zum Nachweis von Infektionen mit dem TBE-Virus und anderen Flaviviren
AU9312598A (en) * 1997-09-10 1999-03-29 Allegheny University Of The Health Sciences Inhibitors of collagen assembly

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9966046A1 *

Also Published As

Publication number Publication date
CA2331197A1 (en) 1999-12-23
AU748700B2 (en) 2002-06-13
NZ508812A (en) 2002-11-26
WO1999066046A1 (fr) 1999-12-23
AU4148999A (en) 2000-01-05

Similar Documents

Publication Publication Date Title
RU2201421C2 (ru) Синтетический пептид hiv (варианты), иммуногенная композиция для индукции иммунного ответа против пептидов hiv, диагностический набор для определения hiv-специфичных антител
JP4278293B2 (ja) Ｈｉｖの増殖を抑える方法及び組成物
WO1999058561A1 (fr) Mimotopes du virus de l'hepatite c
CN104507496B (zh) 包含与crm197载体蛋白偶联的hiv gp41肽的免疫原性化合物
CA2638662A1 (fr) Sequences peptidiques specifiques des stades hepatiques de p. falciparum porteuses d'epitopes capables de stimuler les lymphocytes t.
EP1851321B1 (de) Hiv-epitope und diese enthaltende pharmazeutische zusammensetzung
Chang et al. Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes
EP1068226B1 (de) Lipopeptide, die eine zytotoxische t-lymphozytenantwort induzieren, mit mindestens einem epitop einer t-helferzelle, und ihre anwendungen als impfstoff
JPH07505412A (ja) Ｃｔｌ応答の誘導
EP1084253A1 (de) Mimotope des hiv virus
FR2806912A1 (fr) UTILISATION DE PROTEINES gp120 ET gp160 MODIFIEES DANS LA BOUCLE V3 DU VIH-1 POUR LA PREPARATION DE COMPOSITIONS VACCINALES ET FORMULATIONS LES CONTENANT
JPH09512561A (ja) ヒト免疫不全ウイルス感染に対する防御用合成ワクチン
EP0835309B1 (de) Impstoff gegen krankheitserreger, zusammensetzung zur behandlung und vorbeugung von hiv infektionen
EP0728203A1 (de) Zu innerem bild eines virenprotein ahnliche peptide
CA1268600A (fr) Molecules comportant au moins une sequence peptidique porteuse d'un epitope caracteristique d'une proteine produite par des cellules infectees par les parasites du paludisme et compositions les contenant
EP1368478B1 (de) Polypeptid, das neutralisierende antikörper gegen hiv induziert
EP1163522A1 (de) Nachweis einer superantigenaktivität in einer biologischen probe
KR101756202B1 (ko) 신규한 ｇｐ41 항원
KR100326938B1 (ko) 지방산이 결합된 합성 펩타이드를 인지질 막에 재조합하여 제조한 조합물 및 그 제조방법
Haro et al. Different approaches to potentiate the immune response induced by a 12-mer synthetic peptide
EP1442124B1 (de) Eine den gp41-zwischenzustand imitierende struktur bildendes polypeptid-antigen
WO2002051865A2 (fr) Antigenes proteiques inducteurs d'anticorps neutralisant le virus vih
WO2005097180A1 (fr) Antigene tat dimerique et ses applications pour la vaccination anti-vih.
FR2614025A1 (fr) Peptides susceptibles d'etre reconnus par des anticorps induits contre des retrovirus d'immunodeficience humaine (virus hiv) leurs applications au diagnostic des infections dues a certains de ces virus et, le cas echeant, a la vaccination contre le sida
FR2851165A1 (fr) Antigene derivant de l'helice c de la proteine gp41

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20010112

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU NL PT SE

17Q First examination report despatched

Effective date: 20030808

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Effective date: 20040616